Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, Kunz K, Kessler L, Echchannaoui H, Chen C-W, Kindler T, Döhner K, Burrows F, Theobald M, Sasca D, Kühn MW. Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with <i>MLL</i> rearrangement or <i>NPM1</i&gt; mutation to venetoclax. haematol [Internet]. 2023Oct.1 [cited 2024Apr.26];108(10):2837-43. Available from: https://haematologica.org/article/view/haematol.2022.282160